• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Director Imran Mir A

    12/17/24 5:00:04 PM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RANI alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    IMRAN MIR A

    (Last) (First) (Middle)
    2051 RINGWOOD AVE

    (Street)
    SAN JOSE CA 95131

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Rani Therapeutics Holdings, Inc. [ RANI ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    12/16/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (Right to Buy) $2.84 12/16/2024 D 101,276 05/25/2024 05/24/2033 Class A Common Stock 101,276 (1) 0 D
    Stock Option (Right to Buy) $4.11 12/16/2024 A 101,276 05/25/2024 05/24/2033 Class A Common Stock 101,276 (1) 101,276 D
    Explanation of Responses:
    1. On December 16, 2024, the exercise price of the stock options has been amended to increase the exercise price to $4.11 per share. There is no change to the expiration dates or the vesting schedule of the options.
    Svai Sanford. Attorney-in-Fact for Mir Imran 12/17/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $RANI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RANI

    DatePrice TargetRatingAnalyst
    8/2/2024$17.00Outperform
    Oppenheimer
    6/14/2024$15.00Buy
    Maxim Group
    6/13/2024$10.00Buy
    Rodman & Renshaw
    4/17/2023$24.00Buy
    BTIG Research
    10/11/2022$15.00Buy
    UBS
    7/27/2022$22.00Buy
    H.C. Wainwright
    6/13/2022$28.00Outperform
    Wedbush
    8/25/2021$24.00Buy
    BTIG
    More analyst ratings

    $RANI
    SEC Filings

    View All

    SEC Form DEF 14C filed by Rani Therapeutics Holdings Inc.

    DEF 14C - Rani Therapeutics Holdings, Inc. (0001856725) (Filer)

    12/5/25 4:05:19 PM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Rani Therapeutics Holdings Inc.

    EFFECT - Rani Therapeutics Holdings, Inc. (0001856725) (Filer)

    12/4/25 12:15:17 AM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Rani Therapeutics Holdings Inc.

    424B5 - Rani Therapeutics Holdings, Inc. (0001856725) (Filer)

    12/3/25 4:42:56 PM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RANI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Rani Therapeutics to Participate in the Evercore Healthcare Conference

    SAN JOSE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the company's management team will participate in the upcoming Evercore Healthcare Conference. Details below: 8th Annual Evercore Healthcare ConferenceDate: Wednesday, December 3, 2025 at 8:45 am E.T.Location: Coral Gables, FLPresenter: Chief Executive Officer, Talat Imran, and Chief Financial Officer, Svai SanfordFormat: Fireside Chat and 1x1 Meetings Interested parties can access the live webcast for this conference from the Investor Relations

    11/24/25 4:05:00 PM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate Update

    – Announced up to $1.085 billion collaboration with Chugai Pharmaceutical Co. for multiple high-value therapeutics – – Completed $60.3 million oversubscribed private placement led by Samsara BioCapital with participation from RA Capital Management, Anomaly, Special Situations Funds, and Invus – – Appointed Abraham Bassan and Vasudev Bailey, Ph.D. to the Board of Directors – – Cash runway expected to extend into 2028 – SAN JOSE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today reported financial results for the third

    11/6/25 4:30:00 PM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rani Therapeutics to Present Preclinical Data on Oral Delivery of Semaglutide via the RaniPill® Capsule at ObesityWeek® 2025

    SAN JOSE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it will present preclinical data on the RaniPill® capsule, the company's oral delivery platform, at ObesityWeek® 2025 taking place both virtually and in-person on November 4-7, 2025 in Atlanta, Georgia. Details of the presentation are as follows: Abstract Title: Oral Semaglutide (RT-116) in Dogs is Bioequivalent to SC Injections and Elicits Similar Weight LossSession Type: Poster SessionPoster Number: 647Location: Georgia World Congress Center,

    10/30/25 8:00:00 AM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RANI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Oppenheimer initiated coverage on Rani Therapeutics with a new price target

    Oppenheimer initiated coverage of Rani Therapeutics with a rating of Outperform and set a new price target of $17.00

    8/2/24 7:39:43 AM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Maxim Group initiated coverage on Rani Therapeutics with a new price target

    Maxim Group initiated coverage of Rani Therapeutics with a rating of Buy and set a new price target of $15.00

    6/14/24 9:10:16 AM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rodman & Renshaw initiated coverage on Rani Therapeutics with a new price target

    Rodman & Renshaw initiated coverage of Rani Therapeutics with a rating of Buy and set a new price target of $10.00

    6/13/24 7:14:35 AM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RANI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Bailey Vasudev Jaiprakash

    4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)

    10/30/25 4:31:44 PM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Bailey Vasudev Jaiprakash

    3 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)

    10/30/25 4:30:21 PM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Bassan Abraham

    4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)

    10/27/25 7:29:24 PM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RANI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Imran Mir A bought $1,260,417 worth of shares (2,083,334 units at $0.60) (SEC Form 4)

    4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)

    10/27/25 7:24:25 PM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Business Officer Mckinley Kate bought $29,993 worth of shares (17,960 units at $1.67) (SEC Form 4)

    4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)

    12/16/24 6:00:49 PM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Imran Talat bought $19,974 worth of shares (10,296 units at $1.94), increasing direct ownership by 2% to 494,751 units (SEC Form 4)

    4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)

    12/10/24 1:12:17 PM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RANI
    Financials

    Live finance-specific insights

    View All

    Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate Update

    - Announced preclinical data demonstrating the bioequivalence of RT-114, a GLP-1/GLP-2 dual agonist (PG-102) delivered orally via the RaniPill® capsule, to subcutaneous administration of PG-102 - - Announced preclinical data demonstrating successful oral delivery of semaglutide via RaniPill® capsule - - Preclinical data of four incretin-based molecules underscores the RaniPill® platform's potential to facilitate the oral delivery of a diverse array of obesity treatments - - Phase 1 study for RT-114 for the treatment of obesity, expected to initiate in mid-2025 - - Conference call today at 4:30 p.m. ET / 1:30 p.m. PT - SAN JOSE, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Rani Therapeut

    3/31/25 4:05:00 PM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rani Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

    SAN JOSE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it plans to release financial results for the fourth quarter and full year ended December 31, 2024 and provide a business update on Monday, March 31, 2025 after the close of trading. Rani's management team will host a conference call and webcast beginning at 4:30 p.m. ET. Conference Call and Webcast Rani Therapeutics will host a conference call and live webcast at 4:30 p.m. ET / 1:30 p.m. PT on March 31, 2025. Individuals interested in listenin

    3/25/25 6:00:00 PM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rani Therapeutics Announces Partnership with ProGen on Development of Oral Obesity Treatment

    ~ New RT-114 obesity program combines ProGen's FC Fusion protein conjugated GLP-1/GLP-2 dual agonist, PG-102, with the RaniPill® capsule designed to provide a differentiated oral delivery mechanism with bioavailability comparable to subcutaneous injection ~ ~ Rani and ProGen to share responsibilities for the development and commercialization of RT-114, including a 50/50 cost and revenue share arrangement ~ ~ Rani to host conference call today at 8:00 a.m. ET/5:00 a.m. PT ~ SAN JOSE, Calif., June 24, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani")(NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and

    6/24/24 7:00:00 AM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RANI
    Leadership Updates

    Live Leadership Updates

    View All

    Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate Update

    – Announced up to $1.085 billion collaboration with Chugai Pharmaceutical Co. for multiple high-value therapeutics – – Completed $60.3 million oversubscribed private placement led by Samsara BioCapital with participation from RA Capital Management, Anomaly, Special Situations Funds, and Invus – – Appointed Abraham Bassan and Vasudev Bailey, Ph.D. to the Board of Directors – – Cash runway expected to extend into 2028 – SAN JOSE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today reported financial results for the third

    11/6/25 4:30:00 PM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rani Therapeutics Announces the Appointments of Abe Bassan and Vasudev Bailey, Ph.D. to Board of Directors

    SAN JOSE, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the appointment of Abraham ("Abe") Bassan and Vasudev Bailey, Ph.D., to its Board of Directors. In conjunction with the new appointments, Andrew Farquharson and Maulik Nanavaty have stepped down from the Board of Directors. "We are thrilled to welcome Abe and Vasudev to our Board of Directors as we enter an exciting new era for Rani, highlighted by both our clinical-stage pipeline and expansion opportunities into high-value therapeutics from our rece

    10/23/25 4:01:45 PM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rani Therapeutics Reports Second Quarter 2023 Financial Results; Provides Corporate Update

    - Expansion of partnership with Celltrion for development of RT-105 to complement existing partnership for RT-111 - Appointment of Kate McKinley as Chief Business Officer - Presentation of three abstracts on RT-102 and RT-112 at the Endocrine Society Annual Conference and selection as winner of Presidential Poster Competition in its category for exceptional scientific work on RT-102 - Presentation of late-breaking abstract on oral delivery of GLP-1 agonist at American Diabetes Association's Scientific Sessions - Plan to initiate Phase 2 study for RT-102 and Phase 1 study for RT-111 in 2H of 2023 SAN JOSE, Calif., Aug. 11, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings,

    8/11/23 4:05:00 PM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RANI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Rani Therapeutics Holdings Inc.

    SC 13G - Rani Therapeutics Holdings, Inc. (0001856725) (Subject)

    11/14/24 3:36:16 PM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Rani Therapeutics Holdings Inc.

    SC 13D/A - Rani Therapeutics Holdings, Inc. (0001856725) (Subject)

    10/17/24 4:32:40 PM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Rani Therapeutics Holdings Inc. (Amendment)

    SC 13D/A - Rani Therapeutics Holdings, Inc. (0001856725) (Subject)

    12/8/23 4:31:53 PM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care